Results 41 to 50 of about 25,148 (309)
FGF-23 and sclerostin in serum and bone of CKD patients
Clinical Nephrology, 2023 Aims: Renal osteodystrophy occurs in the early stages of chronic kidney disease (CKD) and progresses during loss of kidney function. Fibroblast growth factor (FGF)-23 and sclerostin, both produced by osteocytes, are increased in blood of patients with ...
Florence Lima +4 more
semanticscholar +1 more source
eLife, 2021 The downregulation of sclerostin in osteocytes mediates bone formation in response to mechanical cues and parathyroid hormone (PTH). To date, the regulation of sclerostin has been attributed exclusively to the transcriptional downregulation of the Sost ...
Nicole R Gould +11 more
doaj +1 more source
Theranostics, 2022 Rationale: Sclerostin inhibition demonstrated bone anabolic potential in osteogenesis imperfecta (OI) mice, whereas humanized therapeutic sclerostin antibody romosozumab for postmenopausal osteoporosis imposed clinically severe cardiac ischemic events ...
Luyao Wang +24 more
semanticscholar +1 more source
Sclerostin: clinical insights in muscle–bone crosstalk
Journal of International Medical Research, 2023 Sclerostin, a protein encoded by the sclerostin (SOST) gene, is mostly expressed in osteocytes. First described in the pathogenesis of three disorders, sclerosteosis, van Buchem’s disease, and craniodiaphyseal dysplasia, sclerostin has been identified as
A. Moretti, G. Iolascon
semanticscholar +1 more source
Osteocyte TSC1 promotes sclerostin secretion to restrain osteogenesis in mice [PDF]
Open Biology, 2019 Osteocytes secrete the glycoprotein sclerostin to inhibit bone formation by osteoblasts, but how sclerostin production is regulated in osteocytes remains unclear.
Wen Liu +14 more
doaj +1 more source
International Journal of Molecular Sciences, 2023 Sclerostin is a bone formation inhibitor produced by osteocytes. Although sclerostin is mainly expressed in osteocytes, it was also reported in periodontal ligament (PDL) fibroblasts, which are cells that play a role in both osteogenesis and ...
Karina E. Pigeaud +8 more
semanticscholar +1 more source
Inhibitors of sclerostin [PDF]
Current Opinion in Rheumatology, 2014 Recent data suggest that inhibitors of sclerostin, an osteocyte-produced Wnt signaling pathway antagonist, can stimulate bone formation. This review provides rationale and summarizes recent evidence supporting this novel approach to skeletal anabolism.Data from numerous preclinical models in rodents and monkeys consistently demonstrate that ...
Matthew T, Drake, Joshua N, Farr
openaire +2 more sources
Sclerostin and Osteocalcin: Candidate Bone-Produced Hormones
Frontiers in Endocrinology, 2021 In addition to its structural role, the skeleton serves as an endocrine organ that controls mineral metabolism and energy homeostasis. Three major cell types in bone - osteoblasts, osteoclasts, and osteocytes – dynamically form and maintain bone and ...
Jialiang S. Wang +2 more
semanticscholar +1 more source
The Role of Sclerostin in Bone Diseases
Journal of Clinical Medicine, 2022 Sclerostin has been identified as an important regulator of bone homeostasis through inhibition of the canonical Wnt-signaling pathway, and it is involved in the pathogenesis of many different skeletal diseases.
E. Vasiliadis +5 more
semanticscholar +1 more source
International Journal of Molecular Sciences, 2023 Sclerostin is a Wnt signaling pathway inhibitor that negatively regulates bone formation. Bone-marrow-derived stromal cell (BMSC) differentiation is influenced by the Wnt pathway, leading to the hypothesis that higher levels of sclerostin might be ...
M. Courtalin +8 more
semanticscholar +1 more source